Pharmafile Logo
Pharmafocus logo
Advanced Search

Acceleron

Showing 4 posts of 4 posts found.

800px-european_commission_flags

Positive CHMP opinion for BMS and Acceleron’s Reblozyl in transfusion-dependent anaemia sub-populations

May 1, 2020
Medical Communications, Sales and Marketing Acceleron, Bristol-Myers Squibb, EU, Reblozyl

Bristol Myers Squibb and Acceleron Pharma’s Reblozyl (luspatercept) has secured a positivr opinion from the European Medicines Agency’s Committee for Medicinal …

News

Celgene and Acceleron’s Reblozyl secures FDA approval for anaemia in beta thalassaemia

November 11, 2019
Sales and Marketing Acceleron, Celgene, Reblozyl, beta thalassaemia, pharma

The FDA has moved to authorise Celgene and Acceleron Pharma’s Reblozyl (luspatercept-aamt) in the treatment of anaemia associated with the …

News
shutterstock_212432119

Acceleron terminates drug candidate following facioscapulohumeral muscular dystrophy failure

September 17, 2019
Manufacturing and Production, Research and Development Acceleron, pharma, trial failure

Acceleron Pharma has seen its stock fall by almost 4% after it unveiled new Phase 2 data confirming that its …

News
celgene_building

Celgene and Acceleron’s blood disorder drug smashes endpoints at Phase 3

July 11, 2018
Research and Development Acceleron, Celgene, beta-thalassemia, luspatercept, pharma

Celgene and Acceleron have lifted the curtain on new Phase 3 data for their erythroid maturation agent (EMA) luspatercept, confirming …

News

Latest content

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024

Veru announces first patients enrolled in phase 2b trial for weight loss treatment

May 1, 2024

Bayer and Evotec to collaborate on precision cardiology

April 30, 2024

PeptiDream and Novartis extend peptide discovery collaboration

April 30, 2024

Pfizer’s Beqvez approved by FDA for haemophilia B treatment

April 29, 2024